Drugs / IFB-088
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03610334 | Jun 2018 → Jun 2019 | — | InFlectis BioScience | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05508074 | Dec 2022 → Nov 2024 | amyotrophic lateral sclerosis | InFlectis BioScience | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IFB-088 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03610334 ↗ |
| Route | Oral | “IFB-088 (2.5-60.0mg) oral capsule” NCT03610334 ↗ |